Foster & Motley Inc. Sells 1,087 Shares of Johnson & Johnson (NYSE:JNJ)

Foster & Motley Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,644 shares of the company’s stock after selling 1,087 shares during the period. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $7,559,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Benchmark Financial Wealth Advisors LLC grew its holdings in Johnson & Johnson by 5.3% in the 3rd quarter. Benchmark Financial Wealth Advisors LLC now owns 1,520 shares of the company’s stock valued at $246,000 after buying an additional 76 shares in the last quarter. Radnor Capital Management LLC acquired a new stake in Johnson & Johnson during the third quarter worth approximately $9,318,000. Wisconsin Capital Management LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $203,000. Catalina Capital Group LLC lifted its position in shares of Johnson & Johnson by 22.2% during the 3rd quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock valued at $1,312,000 after acquiring an additional 1,473 shares during the period. Finally, Avidian Wealth Enterprises LLC raised its stake in Johnson & Johnson by 2.8% in the third quarter. Avidian Wealth Enterprises LLC now owns 16,749 shares of the company’s stock valued at $2,714,000 after purchasing an additional 452 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. TD Securities decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $157.76 on Thursday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a fifty day simple moving average of $162.96 and a two-hundred day simple moving average of $155.76. The firm has a market cap of $379.83 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the company earned $2.66 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.14%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.